Silexion Therapeutics Corp. selects AMS as CRO for Phase 2/3 clinical trials of SIL204, showing up to 97% inhibition rates in preclinical studies. Phase 2/3 trials expected to start in H1 2026 after Q4 2025/Q1 2026 regulatory submissions. AMS brings 28 years of oncology trial expertise to support upcoming trials in KRAS-driven cancers. SIL204 demonstrates significant inhibition rates across pancreatic, colorectal, and lung cancer models, promising potential for transformative RNAi therapy. Collaboration with AMS to focus on dual-route administration in locally advanced pancreatic cancer patients. Silexion aims to push boundaries in oncology therapy with innovative treatments.

Read more at GlobeNewswire: Silexion Therapeutics Announces Selection of Contract